SCHEMBL33530704

SCHEMBL33530704

COCC1=NCCc2c(Br)cccc21

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 1/20 0.36
PARP11 Q9NR21 1/20 0.36
GRM5 P41594 3/20 0.36
GRM1 Q13255 3/20 0.36
KDM4E B2RXH2 2/20 0.32
GLA P06280 1/20 0.32
RCE1 Q9Y256 1/20 0.32
PIM1 P11309 1/20 0.32
CSNK1A1 P48729 1/20 0.32
CDK5 Q00535 1/20 0.32
ROCK1 Q13464 1/20 0.32
DYRK1A Q13627 1/20 0.32
LRRK2 Q5S007 1/20 0.32
CLK4 Q9HAZ1 1/20 0.32
DYRK1B Q9Y463 1/20 0.32
ALDH1A1 P00352 1/20 0.31
HTR2C P28335 1/20 0.30
HTR1A P08908 1/20 0.30
ADRA2A P08913 1/20 0.30
ADRA2B P18089 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL33531892 0.84 PARP10 (0.40) PARP10PARP11GRM5GRM1KDM4E
SCHEMBL2792207 0.82 CYP19A1 (0.42) GRM5KDM4EGLARCE1HTR2C
Hydrochloric Acid SCHEMBL329787 0.81 ADRA1A (0.33) HTR2CHTR1A
SCHEMBL33531923 0.80 PARP10 (0.37) PARP10PARP11GRM5GRM1KDM4E
SCHEMBL7338667 0.74 KDM4E (0.54) KDM4EGLARCE1ALDH1A1HTR2C
SCHEMBL30117138 0.74 SCN9A (0.33) GRM5GRM1KDM4EALDH1A1HTR2C
SCHEMBL1011067 0.74 PARP10 (0.42) PARP10PARP11GRM5GRM1KDM4E
SCHEMBL29607356 0.74 PARP10 (0.42) PARP10PARP11GRM5GRM1KDM4E
SCHEMBL25413811 0.70 KDM4E (0.43) PARP10PARP11KDM4EGLARCE1
SCHEMBL31107139 0.70 KDM4E (0.43) PARP10PARP11KDM4EGLARCE1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION AMPHISTA THERAPEUTICS LTD (GB) 2026-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260092061-A1 COMPOUNDS FOR TARGETED PROTEIN DEGRADATION BCL9L, RBBP9, BRD9 PARP10 1840/4885PARP11 1515/4885GRM5 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.